Log in

NYSE:EQEquillium Stock Price, Forecast & News

$3.45
-0.08 (-2.27 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.30
Now: $3.45
$3.70
50-Day Range
$2.43
MA: $2.87
$3.53
52-Week Range
$2.20
Now: $3.45
$7.45
Volume15,593 shs
Average Volume27,420 shs
Market Capitalization$61.01 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Equillium, Inc., a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was founded in 2017 and is headquartered in San Diego, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.16 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIP29078E105
Phone858-412-5302

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees11
Market Cap$61.01 million
Next Earnings Date8/10/2020 (Estimated)
OptionableNot Optionable

Receive EQ News and Ratings via Email

Sign-up to receive the latest news and ratings for EQ and its competitors with MarketBeat's FREE daily newsletter.

Equillium (NYSE:EQ) Frequently Asked Questions

How has Equillium's stock been impacted by COVID-19 (Coronavirus)?

Equillium's stock was trading at $3.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, EQ stock has decreased by 1.4% and is now trading at $3.45. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Equillium?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Equillium in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Equillium.

When is Equillium's next earnings date?

Equillium is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Equillium.

How were Equillium's earnings last quarter?

Equillium (NYSE:EQ) announced its quarterly earnings data on Wednesday, May, 13th. The company reported ($0.45) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.42) by $0.03. View Equillium's earnings history.

What price target have analysts set for EQ?

2 brokers have issued 12 month price targets for Equillium's shares. Their forecasts range from $14.00 to $14.00. On average, they anticipate Equillium's share price to reach $14.00 in the next year. This suggests a possible upside of 305.8% from the stock's current price. View analysts' price targets for Equillium.

Has Equillium been receiving favorable news coverage?

News headlines about EQ stock have been trending negative this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Equillium earned a daily sentiment score of -2.5 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutEquillium.

Who are some of Equillium's key competitors?

What other stocks do shareholders of Equillium own?

Who are Equillium's key executives?

Equillium's management team includes the following people:
  • Mr. Daniel Mark Bradbury, CEO & Chairman (Age 58)
  • Dr. Stephen Connelly, Chief Scientific Officer & Director (Age 37)
  • Dr. Krishna R. Polu, Chief Medical Officer (Age 46)
  • Mr. Bruce D. Steel C.F.A., Co-Founder, Pres, Chief Bus. Officer & Director (Age 53)
  • Mr. Jason A. Keyes, Chief Financial Officer (Age 48)

When did Equillium IPO?

(EQ) raised $70 million in an IPO on Friday, October 12th 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and Stifel acted as the underwriters for the IPO.

What is Equillium's stock symbol?

Equillium trades on the New York Stock Exchange (NYSE) under the ticker symbol "EQ."

Who are Equillium's major shareholders?

Equillium's stock is owned by a variety of retail and institutional investors. Top institutional investors include Victory Capital Management Inc. (12.48%), Victory Capital Management Inc. (12.48%) and Alyeska Investment Group L.P. (1.62%). View institutional ownership trends for Equillium.

Which institutional investors are selling Equillium stock?

EQ stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Victory Capital Management Inc., and Alyeska Investment Group L.P.. View insider buying and selling activity for Equillium.

How do I buy shares of Equillium?

Shares of EQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Equillium's stock price today?

One share of EQ stock can currently be purchased for approximately $3.45.

How big of a company is Equillium?

Equillium has a market capitalization of $61.01 million. Equillium employs 11 workers across the globe.

What is Equillium's official website?

The official website for Equillium is www.equilliumbio.com.

How can I contact Equillium?

The company can be reached via phone at 858-412-5302.

This page was last updated on 6/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.